Malignant Neoplasm of Stomach Active Not Recruiting Phase 2 Trials for Capecitabine (DB01101)

Also known as: Cancer, Gastric / Gastric Malignancies / Stomach Cancer / Gastric Cancers / Gastric Cancer / Gastric malignancy / Gastric cancer NOS / Cancer of Stomach / Malignant neoplasm of stomach, unspecified

IndicationStatusPhase
DBCOND0045917 (Malignant Neoplasm of Stomach)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03472365A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric CancerTreatment
NCT03342937KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric CancerTreatment
NCT01191697CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric CancerTreatment
NCT00183898Study of Oxaliplatin and Xeloda and Cetuximab as First Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction CancerTreatment
NCT01412294XParTS: Capecitabine/Cisplatin(XP) for Recurrent Gastric CancerTreatment
NCT01406249XParTS II: Capecitabine/CDDP(XP) and S-1/CDDP(SP) as the First-line Treatment for Advanced Gastric CancerTreatment
NCT00674167The Effect of Preoperative Docetaxel, Cisplatin and Capecitabine on Serum RUNX3 Hypermethylation Status in Patients With Gastric and Lower Oesophagus AdenocarcinomaTreatment
NCT00938470Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal JunctionTreatment